The pharmaceutical industry's decades-long struggle to develop effective Alzheimer's treatments may finally gain strategic direction through newly defined therapeutic benchmarks. Rather than continuing the trial-and-error approach that has yielded countless failures, researchers now have concrete targets for what successful prevention therapies should achieve before symptoms appear. The framework establishes specific efficacy thresholds, safety parameters, and measurable endpoints that drug developers must meet to demonstrate meaningful clinical benefit. These profiles focus on interventions administered during preclinical stages when amyloid plaques and tau tangles are accumulating but cognitive decline hasn't yet manifested. The benchmarks specify minimum delays in symptom onset, acceptable risk profiles for healthy individuals, and biomarker changes that correlate with clinical meaningfulness. For instance, a successful preventive therapy might need to delay dementia onset by at least 3-5 years while maintaining safety margins appropriate for long-term use in asymptomatic populations. This represents a fundamental shift from treating existing dementia to intercepting the disease process years earlier. The implications extend far beyond Alzheimer's research, potentially revolutionizing how the field approaches neurodegenerative prevention. However, significant challenges remain in validating these benchmarks through actual clinical trials, which require enormous patient cohorts followed for extended periods. The framework also assumes our current understanding of Alzheimer's pathophysiology is sufficiently accurate to guide prevention strategies. While this standardization could accelerate regulatory approval pathways and attract investment, the ultimate test will be whether therapies meeting these profiles actually translate to meaningful protection against cognitive decline in real-world populations.